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ABSTRACT 
The susceptibility of clinical isolates of Staphylococcus aureus from a hospital to seven antibiotics; namely ofloxacin, vancomycin, oxacillin, 
erythromycin ampicillin and gentamicin was examined. The isolates were recovered from wound, skin, urine, blood, vaginal, cerebrospinal fluid 
and ear infections. After confirmation as S. aureus through gram stain and biochemical tests, the antibiogram of each isolate was determined using 
the disk diffusion method. A total of 214 S. aureus isolates were examined of which 28 (13.1%) were resistant to methicillin. Of these 25% were 
sensitive to ofloxacin, 85.7% to vancomycin, 10.7% to erythromycin 0% to ampicillin and gentamicin. Four (14.3%) of the Methicillin resistant 
isolates were also resistant to vancomycin and all other antibiotics. There was a significant difference in the sensitivity pattern between inpatient 
isolates and outpatient isolates in this study (p <0.05). This study established the presence of methicillin resistant Staphylococcus aureus (MRSA) as 
well as VRSA in this locality and hence the need to implement measures that will limit the dissemination of these strains in the hospital and the 
community. 
INTRODUCTION  
Staphylococcus aureus is a gram-positive pathogen that causes a 
wide range of infections including life-threatening ones. S. 
aureus causes bloodstream infections, skin and soft tissue 
infections as well as pneumonia [1]. Rates of S. aureus infection 
have increased during the past 2 decades [2]. Bacteremia due 
to S. aureus has been reported to be associated with very high 
mortality rates [3]. Methicillin-resistant Staphylococcus aureus 
(MRSA) has occurred in many countries since its discovery in 
1961 [4].  
The emergence of antibiotic-resistant strains, particularly 
MRSA is recognized as very serious health problem because of 
difficulties in combating these strains [5].  
Infections with antibiotic-resistant organisms generally result 
in higher morbidity and mortality rates than are similar 
infections with antibiotic-susceptible strains [6]. 
In recent years, clinicians have been concerned by the 
increased frequency of MRSA infections [7]. This resurging 
MRSA problem seems to be based on the lack of potent 
therapeutic agents having an unequivocal cell-killing effect, 
and thus capable of eliminating MRSA from the patient's body 
[8]. MRSA strains are often resistant to multiple antibiotics and 
pose serious challenges in both hospitals and the community 
[9]. MRSA infections are associated with significant increases 
in mortality, longer hospital stays and higher inpatient costs 
compared to patients with methicillin susceptible S. aureus  
[10,11]. Initially MRSA was considered a nosocomial problem, 
however community-associated methicillin-resistant S. aureus 
(CMRSA) has become the most frequent cause of skin and soft 
tissue infections [12]. 
 
Since the emergence of MRSA, vancomycin has been the most 
reliable therapeutic agent against infections caused by 
methicillin-resistant Staphylococcus aureus (MRSA). However, 
in  1997, the first clinical isolate of Staphylococcus aureus with  
 
 
reduced susceptibility to vancomycin was reported,  [13] and 
by 2001 Vancomycin resistant S. aureus (VRSA) strains  had 
been isolated in  USA, France, Korea, South Africa, and Brazil 
[8]. A certain group of S aureus, designated hetero-VRSA, 
frequently generate VRSA upon exposure to vancomycin, and 
are associated with infections that are potentially refractory to 
vancomycin therapy [8]. 
The present study sought to determine the prevalence of 
MRSA and VRSA and hence the extent of the problem in 
clinical isolates of S. aureus since there is a paucity of published 
data in this locality.   
 
MATERIALS AND METHODS 
S. aureus isolates were obtained from various clinical samples 
at the Microbiology Laboratory University of Abuja Teaching 
Hospital and National Hospital from April 2010 to June 2011.  
For each specimen of a patient only one positive isolate was 
included in the study. Specimens were categorized as 
inpatients or outpatient using the definition of nosocomial 
infection as a localized or systemic condition that results from 
adverse reaction to the presence of an infectious agent not 
present or incubating at the time of admission to the hospital 
according to the Centers for Disease Control and Prevention 
[14]. S. aureus strains were identified by colony morphology, 
pigmentation and growth on Mannitol salt agar (Merk), Gram 
stain, catalase activity, and slide coagulase tests. Using a 0.5 
McFarland-equivalent suspension of organisms inoculated on 
a Mueller-Hinton agar plate (Oxoid, Basingstoke,). Isolates 
were tested using antibiotic discs obtained from Oxoid, 
Basingstoke. The isolates were tested for methicillin resistance 
using oxacillin discs (1 µg) and for vancomycin resistance 
using vancomycin discs (5 µg) as recommended by Andrews 
[15]. Susceptibility of the isolates to other antibiotics namely; 
gentamicin (10 µg), Ofloxacin (5 µg), erythromycin (5 µg), 
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ampicillin (25 µg) was also determined as recommended by 
Andrews [15].  
 
Statistical Analysis 
Chi-square (χ2) test was performed using The Primer of 
Biostatistics soft ware (McGraw-Hill version 4.0). It was used 
to analyze data from resistance of inpatient and outpatient 
MRSA and MSSA strains to antibiotics to determine if there 




The total number of S. aureus strains examined was 214.  Of 
these 33(15.4%) originated from the wound, 30(14%) from 
urine, 85(39.7%) from the blood, 10(4.7%) from the vagina, 
6(2.8%) from hair scalp, 6(2.8%) from ear infections, 42(19.6%) 
from the skin and 2(0.9%) from cerebrospinal fluid. The total 
number of isolates from inpatients was 114 while 100 were 
from outpatients.  
Out of the total number of 214 isolates tested, 28 were MRSA 
and of these 4 were also VRSA. 20 of the MRSA were from 
inpatients and 8 MRSA were from outpatients. Vancomycin 
resistance was not detected in any of the outpatient isolates. 
The highest number of MRSA was detected in blood isolates 
(11) followed by wound (7), 4 were detected in urine and skin 
isolates whilst 2 were detected in cerebrospinal fluid. 
Generally the number of MRSA detected in inpatients was 
higher than in outpatients.  In terms of proportion of number 
of MRSA detected to the total number of isolates examined for 
each type of specimen, cerebrospinal fluid specimens had the 
highest value with all two isolates being MRSA i.e. 100%. This 
was followed by wound swabs in which 7 out of 33 (21%) were 
MRSA, urine samples with 4 out 30 (13.3%), blood with 11 out 
of 85 (12.9%) and skin swabs 4 out 42(9.5%0) respectively. 
MRSA was not detected from vaginal swab, hair scalp and ear 
infections samples. As earlier stated out of the 28 MRSA 
isolates, 4 were also VRSA. These originated from 
cerebrospinal fluid, wound and blood samples. One out of the 
4 MRSA isolated from wound was also a VRSA, 1 out of 2 from 
cerebrospinal fluid was VRSA while 2 out of 10 of blood were 
MRSA. 
Apart from oxacillin and vancomycin other antibiotics tested 
against the isolates were erythromycin, gentamicin, ampicillin 
and ofloxacin.  
 
 
TABLE 1: DISTRIBUTION OF MRSA, MSSA AND VRSA STRAINS ACCORDING TO THEIR ORIGIN. 
 







Total, n (%) 
 inpatient  outpatient Inpatient outpatient  
 Wound 
 
4(1) 3(0) 14(0) 12(0) 33(15.4) 
Urine 2(0) 2(0) 16(0) 10(0) 30(14) 
blood  10(2) 1(0) 50(0) 24(0) 85(39.7) 
Vaginal 0(0) 0(0) 6(0) 4(0) 10(4.7) 
hair scalp  0(0) 0(0) 0(0) 6(0) 6(2.8) 
ear infections 0(0) 0(0) 2(0) 4(0) 6(2.8) 
Skin 2(0) 2(0) 6(0) 32(0) 42(19.6) 
Cerebrospinal fluid 2(1) 0(0) 0(0) 0(0) 2(0.9) 
Values in brackets indicate the number of VRSA in a particular group out of the total. 
 
TABLE 2 ANTIBIOTIC RESISTANCE PATTERNS IN MRSA AND MSSA ISOLATES TO SELECTED ANTIBIOTICS 
 
















Sensitive Resistant Sensitive Resistant  Sensitive Resistant Sensitive Resistant  
Erythromycin 2 18 1 7 25(89.3) 60 34 79 13 47(25.3) 
Ofloxacin 4 16 3 5 21(75.0) 79 15 71 21 36(19.4) 
Vancomycin 16 4 8 0 4(14.3) 94 0 92 0 0(0) 
Ampicillin 0 20 0 8 28 (100) 0 94 2 90 184(98.9) 




Approximately fourteen percent of MRSA isolates were also 
resistant to vancomycin, 75% to ofloxacin, 89.3% to 
erythromycin and 100% to ampicillin and gentamicin 
respectively. Among the MSSA none (0%) was resistant to 
vancomycin, 19.4% was resistant to ofloxacin, 25.3% to 
erythromycin, 59.6% to gentamicin and 98.9% to ampicillin 
respectively.  The difference in resistance of inpatient and 
outpatient MRSA strains to other antibiotics was significantly  
different (p <0.05). Similarly, the difference in resistance of 
inpatient and outpatient MSSA strains to other antibiotics was 
also significantly different (p <0.05). 
In all, three of VRSA were not susceptible to any of the other 





MRSA has caused problems in most hospitals worldwide and 
increasing numbers have been reported in a number of 
countries. There have been significant increases in methicillin 
resistance in clinical strains of S. aureus isolates between 1999 
and 2002 in European countries, particularly Belgium, 
Germany, Ireland, the Netherlands and the United Kingdom 
[16]. MRSA prevalence varied widely, from less than 1% in 
northern Europe to greater than 40% in Southern and Western 
Europe [16].   
In this study 13.1% of S. aureus isolates were resistant to 
methicillin. This figure is less than 20.6% and 47.8% reported 
from Southwestern Nigeria [17, 18] and 69% reported in Zaria 
northern Nigeria [19].   The low rate of MRSA in this study 
may be due to low level of abuse of antibiotics in this locality 
by both health practitioners and in the community since 
emergence of resistant strains has been largely due to antibiotic 
abuse. Moreover MSSA strains were largely susceptible to 
other antibiotics and none was resistant to vancomycin. 
Most of the MRSA isolates were also resistant to other 
antibiotics. The presence of mec A gene complex  which 
specifies the production of an abnormal penicillin binding 
protein PBP2a  that has a decreased affinity for binding β-
lactam antibiotics results in resistance to methicillin and also to 
all β-lactams including penicillins and cephalosporins also 
contains insertion sites for plasmids and transposons that 
facilitate acquisition of resistance to other antibiotics. Thus, 
cross-resistance to non-β-lactam antibiotics such as 
erythromycin, clindamycin, gentamicin, co-trimoxazole and 
ciprofloxacin is common [7].  
MRSA was higher in inpatients expectedly because of 
established MRSA risk factors, such as recent hospitalization, 
surgery, residence in a long-term care facility, receipt of 
dialysis, or presence of invasive medical devices [20].  
Detection of MRSA from outpatients warrants more 
investigation because community associated MRSA (CA-
MRSA) has emerged in the community with clinical, 
epidemiologic, and bacteriologic characteristics distinct from 
healthcare-associated MRSA [21,22,23].  CA-MRSA isolates 
also tend to be resistant to fewer antimicrobial classes, possess 
different toxin genes, and carry a different type of the gene 
complex known as staphylococcal cassette chromosome mec 
(SCCmec), which contains the mec A methicillin-resistance gene 
[24, 25]. The resistance of outpatient isolates to different 
antibiotics appeared to be less than those from inpatients but 
this remains to be confirmed by larger studies because of the 
limited data from the present study. The higher susceptibility 
pattern of MSSA to antibiotics seems to confirm the tendency 
of MRSA to acquire resistance genes to other antibiotics.  
Vancomycin resistance was observed in 4 isolates and only one 
of which was susceptible to any other antibiotics. The reported 
prevalence  rate of VRSA in southern parts of Nigeria range 
from 0% to 6% among clinical isolates in agreement with the 
present study [17,18].  A prevalence rate 57.7% has also been 
reported in Zaria northern Nigeria [26] and in another study in 
non clinical isolates  a prevalence rate 89%  was reported [19].  
The difference in rates of vancomycin resistance is probably 
reflects differences in levels of over prescription and abuse in 
different parts of the country   This study as well as others 
might  however have underestimated vancomycin resistance   
because of the inability of routine antimicrobial susceptibility 
test methods to detect heterogeneous vancomycin-
intermediate Staphylococcus aureus (hVISA) and vancomycin-
intermediate Staphylococcus aureus VISA detected in different 
continents [27-30 ]. Vancomycin resistant strains are a source of 
concern because until recently, vancomycin was the only 
uniformly effective treatment for staphylococcal infections 
particularly MRSA. Resistance to vancomycin severely limits 
treatment options as seen in this study.  
Although the incidence of MRSA and VRSA observed in this 
study has not reached epidemic proportions, it is still very 
important to put in measures to contain their spread and 
continue surveillance both in healthcare facilities and in the 
community. The spread of these pathogens in the community 
can result in skin infections and, less commonly, invasive 
infections among otherwise healthy adults and children in the 
community.
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